Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 19/20 | 1.00 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.81 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.81 |
| ▸ | NPC1 | O15118 | 1/20 | 0.68 |
| ▸ | MAPT | P10636 | 1/20 | 0.68 |
| ▸ | RAB9A | P51151 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30674787 | 0.92 | MAOB (1.00) | MAOBCYP19A1CYP3A4 | |
| Liquiritigenin Dimethyl Ether SCHEMBL3303937 | 0.89 | CYP19A1 (1.00) | MAOBCYP19A1CYP3A4NPC1MAPT | |
| Liquiritigenin Dimethyl Ether SCHEMBL13394438 | 0.89 | CYP19A1 (1.00) | MAOBCYP19A1CYP3A4NPC1MAPT | |
| SCHEMBL11242835 | 0.85 | MAOB (0.81) | MAOBCYP19A1CYP3A4NPC1MAPT | |
| SCHEMBL7195893 | 0.85 | CYP19A1 (0.86) | MAOBCYP19A1CYP3A4NPC1MAPT | |
| SCHEMBL18893710 | 0.85 | MAOB (0.81) | MAOBCYP19A1CYP3A4NPC1MAPT | |
| SCHEMBL30777574 | 0.85 | MAOB (0.81) | MAOBCYP19A1CYP3A4NPC1MAPT | |
| SCHEMBL31028354 | 0.85 | CYP19A1 (0.86) | MAOBCYP19A1CYP3A4NPC1MAPT | |
| SCHEMBL10360819 | 0.84 | MAOB (1.00) | MAOBCYP19A1 | |
| SCHEMBL10360962 | 0.84 | MAOB (1.00) | MAOBCYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4662319-A2 | PERSONALIZED CRISPR PROFILING FOR CANCER | Integrate Bioscience LLC (US) | 2025-12-17 | — | — | EP | disclosed |
| WO-2024168301-A2 | PERSONALIZED CRISPR PROFILING FOR CANCER | FUNCTION ONCOLOGY, INC. (US) | 2024-08-15 | — | — | WO | disclosed |